Article

Clinical and Molecular Findings in Osteoporosis-Pseudoglioma Syndrome

Department of Genetics and Center for Human Genetics, Case School of Medicine and University Hospitals of Cleveland, Cleveland, OH, 44106, USA.
The American Journal of Human Genetics (Impact Factor: 10.99). 12/2005; 77(5):741-53. DOI: 10.1086/497706
Source: PubMed

ABSTRACT Mutations in the low-density lipoprotein receptor-related protein 5 gene (LRP5) cause autosomal recessive osteoporosis-pseudoglioma syndrome (OPPG). We sequenced the coding exons of LRP5 in 37 probands suspected of having OPPG on the basis of the co-occurrence of severe congenital or childhood-onset visual impairment with bone fragility or osteoporosis recognized by young adulthood. We found two putative mutant alleles in 26 probands, only one mutant allele in 4 probands, and no mutant alleles in 7 probands. Looking for digenic inheritance, we sequenced the genes encoding the functionally related receptor LRP6, an LRP5 coreceptor FZD4, and an LRP5 ligand, NDP, in the four probands with one mutant allele, and, looking for locus heterogeneity, we sequenced FZD4 and NDP in the seven probands with no mutations, but we found no additional mutations. When we compared clinical features between probands with and without LRP5 mutations, we found no difference in the severity of skeletal disease, prevalence of cognitive impairment, or family history of consanguinity. However, four of the seven probands without detectable mutations had eye pathology that differed from pathology previously described for OPPG. Since many LRP5 mutations are missense changes, to differentiate between a disease-causing mutation and a benign variant, we measured the ability of wild-type and mutant LRP5 to transduce Wnt and Norrin signal ex vivo. Each of the seven OPPG mutations tested, had reduced signal transduction compared with wild-type mutations. These results indicate that early bilateral vitreoretinal eye pathology coupled with skeletal fragility is a strong predictor of LRP5 mutation and that mutations in LRP5 cause OPPG by impairing Wnt and Norrin signal transduction.

0 Followers
 · 
117 Views
  • Source
    • "Accordingly, patients carrying rare gain-of-function (GoF) LRP5 mutations exhibit high bone mass (HBM) (Boyden et al., 2002; Little et al., 2002). Reciprocally , rare loss-of-function (LoF) LRP5 mutations lead to osteoporosis (Ai et al., 2005; Gong et al., 2001), which, in a study of 12 affected probands from two families, was coupled with an increased prevalence of T2D (Saarinen et al., 2010). Finally, rare inactivating missense mutations in LRP6 result in autosomal dominant CVD, features of the metabolic syndrome, and osteoporosis (Mani et al., 2007; Singh et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Common variants in WNT pathway genes have been associated with bone mass and fat distribution, the latter predicting diabetes and cardiovascular disease risk. Rare mutations in the WNT co-receptors LRP5 and LRP6 are similarly associated with bone and cardiometabolic disorders. We investigated the role of LRP5 in human adipose tissue. Subjects with gain-of-function LRP5 mutations and high bone mass had enhanced lower-body fat accumulation. Reciprocally, a low bone mineral density-associated common LRP5 allele correlated with increased abdominal adiposity. Ex vivo LRP5 expression was higher in abdominal versus gluteal adipocyte progenitors. Equivalent knockdown of LRP5 in both progenitor types dose-dependently impaired β-catenin signaling and led to distinct biological outcomes: diminished gluteal and enhanced abdominal adipogenesis. These data highlight how depot differences in WNT/β-catenin pathway activity modulate human fat distribution via effects on adipocyte progenitor biology. They also identify LRP5 as a potential pharmacologic target for the treatment of cardiometabolic disorders. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Cell Metabolism 02/2015; 21(2):262-72. DOI:10.1016/j.cmet.2015.01.009 · 16.75 Impact Factor
  • Source
    • "To study the cellular and molecular mechanisms underlying high bone mass phenotype in the above mentioned family, we generated BMSC lines that overexpress the wild type LRP5, LRP5 with T253I (the gain-of-function mutation found in HBM family described above) or loss-of-function T244M mutation described in OPPG patients [91]. Our data demonstrated that overexpression of LRP5 T253I in hBMSCs increased canonical Wnt signaling in response to Wnt3a stimulation and this was associated with enhanced osteoblast differentiation and inhibition of adipocyte differentiation of hBMSCs [106], suggesting that LRP5 T253I mutation enhances commitment of BMSCs into osteoblast and not adipocyte lineage [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal (marrow stromal) stem cells (BMSCs) are a group of multipotent cells that reside in the bone marrow stroma and can differentiate into osteoblasts, chondrocytes and adipocytes. Studying signaling pathways that regulate BMSCs differentiation into osteoblastic cells is a strategy for identifying druggable targets for enhancing bone formation. This review will discuss the functions and the molecular mechanisms of action on osteoblast differentiation and bone formation; of a number of recently identified regulatory molecules: the non-canonical Notch signaling molecule Delta-like 1/preadipocyte factor 1 (Dlk1/Pref-1), the Wnt co-receptor Lrp5 and intracellular kinases.
    Bone 08/2014; 70. DOI:10.1016/j.bone.2014.07.028 · 4.46 Impact Factor
  • Source
    • "Using standard PCR-based sequencing, we detected three novel LRP5 mutations (c.1145C>T, p.P382L; c.1584þ1G>A [splice donor site in intron 7]; and c.1655C>T, p.T552M) and three previously described mutations [c.433C>T, p.L145F, Qin et al., 2005; c.731C>T, p.T244M, Ai et al., 2005; and c.4600C>T, p.R1534X, Gong et al., 2001] in the four OPS patients (Fig. 1A). These mutations were not found in 100 control individuals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis-pseudoglioma syndrome (OPS; OMIM 259770) is an autosomal-recessive genetic disorder characterized by severe osteoporosis and visual disturbance from childhood. Biallelic mutations in the low-density lipoprotein receptor-related protein 5 gene (LRP5) have been frequently detected, while a subset of patients had only one or no detectable mutation. We report on the clinical and molecular findings of four unrelated Japanese patients with the syndrome. The four patients had typical skeletal and ocular phenotypes of OPS, namely severe juvenile osteoporosis and early-onset visual disturbance, with or without mental retardation. We undertook standard PCR-based sequencing for LRP5 and found four missense mutations (p.L145F, p.T244M, p.P382L, and p.T552M), one nonsense mutation (p.R1534X), and one splice site mutation (c.1584+1G>A) among four OPS patients. Although three patients had two heterozygous mutations, one had only one heterozygous splice site mutation. In this patient, RT-PCR from lymphocytic RNA demonstrated splice error resulting in 63-bp insertion between exons 7 and 8. Furthermore, the patient was found to have only mutated RT-PCR fragment, implying that a seemingly normal allele did not express LRP5 mRNA. We then conducted custom- designed oligonucleotide tiling microarray analyses targeted to a 600-kb genome region harboring LRP5 and discovered a 7.2-kb microdeletion encompassing exons 22 and 23 of LRP5. We found various types of LRP5 mutations, including an exon-level deletion that is undetectable by standard PCR-based mutation screening. Oligonucleotide tiling microarray seems to be a powerful tool in identifying cryptic structural mutations.
    American Journal of Medical Genetics Part A 01/2010; 152A(1):133-40. DOI:10.1002/ajmg.a.33177 · 2.05 Impact Factor
Show more